Increased expression of CC16 in patients with idiopathic pulmonary fibrosis

PLoS ONE

Volumn 11, Issue 12, 2016, Pages

  Buendía Roldán, Ivette ^a   Ruiz, Víctor ^a   Sierra, Patricia ^a   Montes, Eduardo ^a   Ramírez, Remedios ^b   Vega, Anita ^a   Salgado, Alfonso ^a   Vargas, Mario H ^a   Mejía, Mayra ^a   Pardo, Annie ^b   Selman, Moisés ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CLUB CELL PROTEIN 16; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; SCGB1A1 PROTEIN, HUMAN; UTEROGLOBIN;

ADULT; AGED; ALLERGIC PNEUMONITIS; ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM CELL; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SENSITIVITY AND SPECIFICITY; UPREGULATION; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHUS; CHEMISTRY; CYTOLOGY; EPITHELIUM CELL; IDIOPATHIC PULMONARY FIBROSIS; LUNG ALVEOLUS; LUNG DISEASES, INTERSTITIAL; METABOLISM; MIDDLE AGED; SEX DIFFERENCE;

AGED; BIOMARKERS; BRONCHI; BRONCHOALVEOLAR LAVAGE FLUID; EPITHELIAL CELLS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PULMONARY ALVEOLI; SEX FACTORS; UTEROGLOBIN;

EID: 85006372434     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0168552     Document Type: Article

References (29)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824. doi: 10.1164/rccm.2009-040GL PMID: 21471066
2. King TE Jr., Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949-1961. doi: 10. 1016/S0140-6736(11)60052-4 PMID: 21719092
3. Guerra S, Halonen M, Vasquez MM, Spangenberg A, Stern DA, Morgan WJ, et al. Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: a prospective study. Lancet Respir Med 2015; 3:613-620. doi: 10.1016/ S2213-2600(15)00196-4 PMID: 26159408
4. Akram KM, Lomas NJ, Spiteri MA, Forsyth NR. Club cells inhibit alveolar epithelial wound repair via TRAIL-dependent apoptosis. Eur Respir J 2013; 41:683-694. doi: 10.1183/09031936.00213411 PMID: 22790912
5. Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007; 175: 705-711. doi: 10.1164/rccm.200607-912OC PMID: 17218621
6. Ohno Y, Koyama H, Yoshikawa T, Seki S. State-of-the-Art Imaging of the lung for connective tissue disease (CTD). Curr Rheumatol Rep 2015; 17:69. doi: 10.1007/s11926-015-0546-8 PMID: 26483318
7. Takemura T, Akashi T, Kamiya H, Ikushima S, Ando T, Oritsu M, et al. Pathological differentiation of chronic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis/usual interstitial pneumonia. Histopathology. 2012; 61:1026-1035. doi: 10.1111/j.1365-2559.2012.04322.x PMID: 22882269
8. Morell F, Villar A, Montero MÁ, Muñoz X, Colby TV, Pipvath S, et al. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med 2013; 1:685-694. doi: 10.1016/S2213-2600(13)70191-7 PMID: 24429272
9. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2071-2082. doi: 10.1056/ NEJMoa1402584 PMID: 24836310
10. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2083-2092. doi: 10.1056/NEJMoa1402582 PMID: 24836312
11. King TE Jr, Lasky JA, Martinez FJ. Idiopathic Pulmonary Fibrosis Clinical Research Network, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366:1968-1977. doi: 10.1056/NEJMoa1113354 PMID: 22607134
12. Hambly N, Shimbori C, Kolb M. Molecular classification of idiopathic pulmonary fibrosis: Personalized medicine, genetics and biomarkers. Respirology 2015; 20: 1010-1022. doi: 10.1111/resp.12569 PMID: 26109466
13. Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2014; 307: L681-L691. doi: 10.1152/ajplung.00014.2014 PMID: 25260757
14. White ES, Xia M, Murray S, Dyal R, Flaherty CM, Flaherty KR, et al. Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2016 May 5. [Epub ahead of print]
15. Selman M, Pardo A, King TE Jr. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med 2012; 186:314-324. doi: 10.1164/rccm.201203-0513CI PMID: 22679012
16. Shiboski SC, Shiboski CH, Criswell LA, Baer AN, Challacombe S, Lanfranchi H, et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance Cohort. Arthritis Care Res. 2012; 64: 475-487.
17. Neogi T, Aletaha D, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum 2010; 62: 2582-2591. doi: 10.1002/art.27580 PMID: 20872596
18. Pardo A, Gibson K, Cisneros J, Richards TJ, Yang Y, Becerril C, et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PloS Med. 2005; 2(9): e251. doi: 10.1371/ journal.pmed.0020251 PMID: 16128620
19. Selman M, Pardo A, Barrera L, Estrada A, Watson SR, Wilson K, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2006; 173: 188-198. doi: 10.1164/rccm.200504-644OC PMID: 16166619
20. Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. An integral model. Am J Respir Crit Care Med. 2014; 189: 1161-1172. doi: 10.1164/rccm.201312-2221PP PMID: 24641682
21. Selman M, King TE, Pardo A; American Thoracic Society; European Respiratory Society; American College of Chest Physicians. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001; 134:136-151. PMID: 11177318
22. Gioldassi XM, Papadimitriou H, Mikraki V, Karamanos NK. Clara cell secretory protein: determination of serum levels by an enzyme immunoassay and its importance as an indicator of bronchial asthma in children. J Pharm Biomed Anal. 2004; 34: 823-826. doi: 10.1016/S0731-7085(03)00570-3 PMID: 15019060
23. Laucho-Contreras ME, Polverino F, Gupta K, Taylor KL, Kelly E, Pinto-Plata V, et al. Protective role for club cell secretory protein-16 (CC16) in the development of chronic obstructive pulmonary disease. Eur Respir J. 2015; 45: 1544-1556. doi: 10.1183/09031936.00134214 PMID: 25700379
24. Guerra S, Vasquez MM, Spangenberg A, Halonen M, Martinez FD. Serum concentrations of club cell secretory protein (Clara) and cancer mortality in adults: a population-based, prospective cohort study. Lancet Respir Med. 2013; 1: 779-785. doi: 10.1016/S2213-2600(13)70220-0 PMID: 24461757
25. Robin M, Dong P, Hermans C, Bernard A, Bersten AD, Doyle IR. Serum levels of CC16, SP-A and SP-B reflect tobacco-smoke exposure in asymptomatic subjects. Eur Respir J. 2002; 20:1152-1161. PMID: 12449168
26. Hasegawa M, Fujimoto M, Hamaguchi Y, Matsushita T, Inoue K, Sato S, et al. Use of serum clara cell 16-kDa (CC16) levels as a potential indicator of active pulmonary fibrosis in systemic sclerosis. J Rheumatol 2011; 38: 877-884. doi: 10.3899/jrheum.100591 PMID: 21239758
27. Olewicz-Gawlik A, Trzybulska D, Kuznar-Kaminska B, Katulska K, Danczak-Pazdrowska A, Batura-Gabryel H, et al. Serum Clara cell 16-kDa protein levels and lung impairment in systemic sclerosis patients. Rev Bras Reumatol Engl Ed. 2016; 56:309-313. doi: 10.1016/j.rbre.2015.07.005 PMID: 27476623
28. Kokuho N, Ishii T, Kamio K, Hayashi H, Kurahara M, Hattori K, et al. Diagnostic values for Club cell secretory protein (CC16) in serum of patients of combined pulmonary fibrosis and emphysema. COPD. 2015; 12:347-354. doi: 10.3109/15412555.2014.948994 PMID: 25244495
29. Oikonomou A, Prassopoulos P. Mimics in chest disease: interstitial opacities. Insights.Imaging 2013; 4:9-27. doi: 10.1007/s13244-012-0207-7 PMID: 23247773